Trade Report: The 14,465 Shares of Seattle Genetics Inc. (SGEN) Stock are sold by Clay B. Siegall

The 14,465 Shares of Seattle Genetics Inc. (SGEN) Stock are sold by Clay B. Siegall

Seattle Genetics Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 14,465 shares of the firm’s stock in a transaction that occurred on Thursday, October 6th. The stock was sold at an average price of $54.41, for a total transaction of $787,040.65. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Clay B. Siegall also recently made the following trade(s): On Thursday, September 8th, Clay B. Siegall sold 31,269 shares of Seattle Genetics stock. The stock was sold at an average price of $50.08, for a total transaction of $1,565,951.52. On Monday, August 22nd, Clay B. Siegall sold 23,381 shares of Seattle Genetics stock. The stock was sold at an average price of $46.59, for a total transaction of $1,089,320.79. On Monday, August 8th, Clay B. Siegall sold 11,660 shares of Seattle Genetics stock. The stock was sold at an average price of $47.19, for a total transaction of $550,235.40. On Wednesday, July 27th, Clay B. Siegall sold 4,042 shares of Seattle Genetics stock. The stock was sold at an average price of $45.20, for a total transaction of $182,698.40.

Seattle Genetics Inc. (NASDAQ:SGEN) opened at 52.29 on Friday. Seattle Genetics Inc. has a 12 month low of $26.02 and a 12 month high of $57.83. The stock’s market cap is $7.35 billion. The stock has a 50 day moving average price of $51.98 and a 200-day moving average price of $43.25.

Seattle Genetics (NASDAQ:SGEN) last issued its quarterly earnings data on Tuesday, July 26th. The company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.09. The firm earned $95.40 million during the quarter, compared to the consensus estimate of $94.56 million. Seattle Genetics had a negative return on equity of 15.29% and a negative net margin of 27.21%. The firm’s revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.38) EPS. On average, analysts expect that Seattle Genetics Inc. will post ($1.00) EPS for the current year.

A number of equities analysts have recently issued reports on SGEN shares. Zacks Investment Research upgraded shares of Seattle Genetics from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Monday, July 4th. SunTrust Banks Inc. raised their target price on shares of Seattle Genetics from $34.00 to $38.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 27th. Cantor Fitzgerald downgraded Seattle Genetics from a “buy” rating to a “hold” rating and set a $43.00 price target for the company. in a report on Wednesday, July 27th. Goldman Sachs Group Inc. downgraded Seattle Genetics from a “neutral” rating to a “sell” rating in a report on Friday, September 16th. Finally, Royal Bank Of Canada increased their price target on Seattle Genetics from $55.00 to $62.00 and gave the stock an “outperform” rating in a report on Monday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company’s stock. Seattle Genetics presently has a consensus rating of “Hold” and a consensus price target of $51.53.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. MSI Financial Services Inc increased its position in shares of Seattle Genetics by 114.0% in the third quarter. MSI Financial Services Inc now owns 1,866 shares of the company’s stock worth $101,000 after buying an additional 994 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Seattle Genetics by 37.5% in the second quarter. JPMorgan Chase & Co. now owns 3,595 shares of the company’s stock worth $145,000 after buying an additional 981 shares during the last quarter. First National Bank of Omaha bought a new position in shares of Seattle Genetics during the third quarter worth approximately $201,000. HighTower Advisors LLC bought a new position in shares of Seattle Genetics during the second quarter worth approximately $206,000. Finally, Carl Domino Inc bought a new position in shares of Seattle Genetics during the second quarter worth approximately $218,000. Hedge funds and other institutional investors own 97.93% of the company’s stock.

Seattle Genetics Company Profile

Related posts

Leave a Comment